Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported results from multiple new preclinical studies demonstrating enhanced anti-tumor activity and immune activation for combinations of a preclinical bavituximab equivalent and checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast cancer and melanoma at the 2015 meeting of the Society for Immunotherapy of Cancer.